Abogen Biosciences

Price —

Potential 0 Risk 0

Track in portfolio

Price chart

AI recommendation Analyst forecast Calendar event Positive signal Negative signal Neutral / update Hold / informational B My buy S My sell

Description

Nothing yet

News Page 1 of 1

Novartis Enters $7.8 Billion Licensing Agreement with Abogen Biosciences Amid Patent Cliff Concerns

10/02/2026, 04:38 AM business announcement biotech healthcare Abogen Biosciences Novartis

Novartis has entered a significant licensing agreement with China's Abogen Biosciences, valued at up to $7.8 billion, as part of a broader trend of Big Pharma seeking innovative treatments amid impending patent expirations.